Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Intangibles (2020 - 2025)

Harvard Bioscience (HBIO) has disclosed Change in Intangibles for 5 consecutive years, with $141000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Intangibles fell 38.96% to $141000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $620000.0, a 9.49% decrease, with the full-year FY2024 number at $619000.0, up 18.36% from a year prior.
  • Change in Intangibles was $141000.0 for Q3 2025 at Harvard Bioscience, down from $144000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $231000.0 in Q4 2023 to a low of $75000.0 in Q1 2024.
  • A 4-year average of $158818.2 and a median of $150000.0 in 2021 define the central range for Change in Intangibles.
  • Biggest YoY gain for Change in Intangibles was 126.67% in 2025; the steepest drop was 38.96% in 2025.
  • Harvard Bioscience's Change in Intangibles stood at $150000.0 in 2021, then soared by 54.0% to $231000.0 in 2023, then dropped by 28.57% to $165000.0 in 2024, then dropped by 14.55% to $141000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Change in Intangibles are $141000.0 (Q3 2025), $144000.0 (Q2 2025), and $170000.0 (Q1 2025).